The PD-L1 antibody is thought to selectively kill tumor cells while upregulating PD-L1 expression in surviving cancer cells and/or increasing the density of tumor-infiltrating lymphocytes, providing an opportunity to achieve a targeted therapeutic activity in a positive feedback manner. This evidence concerns the gene CD274 and cancer.